Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
Phase II, Metastatic Breast Cancer
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Intervention
Name: Lipo-Dox
Type: Drug
Overall Status
Recruiting
Summary
To determine the overall objective response rate of pegylated liposomal doxorubicin (Lipo-Dox)combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 20 Years
Gender: Both
Criteria: Inclusion Criteria:

- histologically proved breast cancer with metastatic disease

Exclusion Criteria:

- life expectancy less than 3 months.
Location
CGMH
Linko, Taiwan
Status: Recruiting
Contact: Wang, AN - +8862-2545-3105 - monicachang@tty.com.tw
Start Date
September 2005
Sponsors
TTY Biopharm
Source
TTY Biopharm
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page